Serving patients with

commitment and humanity

Clinical Trials


We are currently evaluating the safety and tolerability of RLY-1971 in a Phase 1 dose escalation study in patients with advanced or metastatic solid tumors.


In August 2021, Genentech initiated the cohort of RLY-1971/GDC-1971, an inhibitor of SHP2, in combination with GDC-6036, an inhibitor of KRAS G12C, in a Phase 1b trial.


We are currently evaluating the safety and tolerability of RLY-4008 in a first-in-human dose escalation study in patients who have FGFR2 alterations in advanced solid tumors.


We are currently evaluating a first-in-human study of pan mutant-selective PI3Kα inhibitor, RLY-2608, as a single agent in advanced solid tumor patients and in combination with fulvestrant in patients with HR+, HER2-, PI3Kα mutated advanced breast cancer.

For questions or interest in participating in our clinical trials, please email us.

Expanded Access Policy

Relay Therapeutics is hyper-focused on bringing life-changing medicines to patients. Our goal is to provide access to our investigational therapies when it is appropriate. Read on to learn more.

We are constantly working with patients, their families, caregivers, and advocacy groups to learn about the challenges patients experience in their daily lives and how we can best support them from a therapeutic perspective and beyond.